Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials
<strong>Background:</strong> Niemann-Pick disease type C (NPC) is a lysosomal storage disease with a heterogeneous neurodegenerative clinical course. Multiple therapies are in clinical trials and inclusion criteria are currently mainly based on age and neurological signs, not taking into...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
BioMed Central
2018
|
| _version_ | 1797056868719263744 |
|---|---|
| author | Cortina-Borja, M Vruchte, D Mengel, E Amraoui, Y Imrie, J Jones, SA Dali, C Fineran, P Kirkegaard, T Runz, H Lachman, R Bremova-Ertl, T Strupp, M Platt, FM |
| author_facet | Cortina-Borja, M Vruchte, D Mengel, E Amraoui, Y Imrie, J Jones, SA Dali, C Fineran, P Kirkegaard, T Runz, H Lachman, R Bremova-Ertl, T Strupp, M Platt, FM |
| author_sort | Cortina-Borja, M |
| collection | OXFORD |
| description | <strong>Background:</strong> Niemann-Pick disease type C (NPC) is a lysosomal storage disease with a heterogeneous neurodegenerative clinical course. Multiple therapies are in clinical trials and inclusion criteria are currently mainly based on age and neurological signs, not taking into consideration differential individual rates of disease progression. <strong>Results:</strong> In this study, we have evaluated a simple metric, denoted annual severity increment score (ASIS), that measures rate of disease progression and could easily be used in clinical practice. We show that ASIS is stable over several years and can be used to stratify patients for clinical trials. It achieves greater homogeneity of the study cohort relative to age-based inclusion and provides an evidence-based approach for establishing inclusion/exclusion criteria. In addition, we show that ASIS has prognostic value and demonstrate that treatment with an experimental therapy - acetyl-DL-leucine - is associated with a reduction in ASIS scores. <strong>Conclusion:</strong> ASIS has the potential to be a useful metric for clinical monitoring, trial recruitment, for prognosis and measuring response to therapy. |
| first_indexed | 2024-03-06T19:28:33Z |
| format | Journal article |
| id | oxford-uuid:1ca607de-3abe-4334-8f1b-248d228b07be |
| institution | University of Oxford |
| last_indexed | 2024-03-06T19:28:33Z |
| publishDate | 2018 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:1ca607de-3abe-4334-8f1b-248d228b07be2022-03-26T11:06:43ZAnnual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trialsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1ca607de-3abe-4334-8f1b-248d228b07beSymplectic Elements at OxfordBioMed Central2018Cortina-Borja, MVruchte, DMengel, EAmraoui, YImrie, JJones, SADali, CFineran, PKirkegaard, TRunz, HLachman, RBremova-Ertl, TStrupp, MPlatt, FM<strong>Background:</strong> Niemann-Pick disease type C (NPC) is a lysosomal storage disease with a heterogeneous neurodegenerative clinical course. Multiple therapies are in clinical trials and inclusion criteria are currently mainly based on age and neurological signs, not taking into consideration differential individual rates of disease progression. <strong>Results:</strong> In this study, we have evaluated a simple metric, denoted annual severity increment score (ASIS), that measures rate of disease progression and could easily be used in clinical practice. We show that ASIS is stable over several years and can be used to stratify patients for clinical trials. It achieves greater homogeneity of the study cohort relative to age-based inclusion and provides an evidence-based approach for establishing inclusion/exclusion criteria. In addition, we show that ASIS has prognostic value and demonstrate that treatment with an experimental therapy - acetyl-DL-leucine - is associated with a reduction in ASIS scores. <strong>Conclusion:</strong> ASIS has the potential to be a useful metric for clinical monitoring, trial recruitment, for prognosis and measuring response to therapy. |
| spellingShingle | Cortina-Borja, M Vruchte, D Mengel, E Amraoui, Y Imrie, J Jones, SA Dali, C Fineran, P Kirkegaard, T Runz, H Lachman, R Bremova-Ertl, T Strupp, M Platt, FM Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials |
| title | Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials |
| title_full | Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials |
| title_fullStr | Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials |
| title_full_unstemmed | Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials |
| title_short | Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials |
| title_sort | annual severity increment score as a tool for stratifying patients with niemann pick disease type c and for recruitment to clinical trials |
| work_keys_str_mv | AT cortinaborjam annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT vruchted annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT mengele annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT amraouiy annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT imriej annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT jonessa annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT dalic annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT fineranp annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT kirkegaardt annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT runzh annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT lachmanr annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT bremovaertlt annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT struppm annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials AT plattfm annualseverityincrementscoreasatoolforstratifyingpatientswithniemannpickdiseasetypecandforrecruitmenttoclinicaltrials |